A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors
Here, the authors provide a panel of medium-throughput assays to test potential drug candidates against different life cycle stages of Cryptosporidium with the goal to support a drug development pipeline that contains compounds with diverse molecular mechanisms of action.
Guardado en:
Autores principales: | Rajiv S. Jumani, Muhammad M. Hasan, Erin E. Stebbins, Liam Donnelly, Peter Miller, Connor Klopfer, Kovi Bessoff, Jose E. Teixeira, Melissa S. Love, Case W. McNamara, Christopher D. Huston |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/03437c7266734301bb9d6a058e5a30f9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis
por: Christopher S. Lunde, et al.
Publicado: (2019) -
Suits and Uniforms
por: Hasan Kösebalaban
Publicado: (2004) -
Ruth Ellis’s Suit
por: Lynda Nead
Publicado: (2021) -
Multilocus sequence subtyping and genetic structure of Cryptosporidium muris and Cryptosporidium andersoni.
por: Rongjun Wang, et al.
Publicado: (2012) -
Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family
por: Abhishek Kumar, et al.
Publicado: (2018)